Renalytix (LSE:RENX) Debt-to-Asset : 1.07 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Renalytix Debt-to-Asset?

Renalytix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £3.56 Mil. Renalytix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was £3.85 Mil. Renalytix's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was £6.90 Mil. Renalytix's debt to asset for the quarter that ended in Mar. 2024 was 1.07.

Renalytix Debt-to-Asset Historical Data

The historical data trend for Renalytix's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Debt-to-Asset Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.25

0.40

Renalytix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.29	0.40	0.54	0.39	1.07

Competitive Comparison of Renalytix's Debt-to-Asset

For the Health Information Services subindustry, Renalytix's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix's Debt-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Renalytix's Debt-to-Asset falls into.

Renalytix Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Renalytix's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.638	+	5.961)	/	24.258
	=	0.40

Renalytix's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.563	+	3.85)	/	6.901
	=	1.07

Renalytix (LSE:RENX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Renalytix Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Renalytix's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (LSE:RENX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

RNLX:USA RTNXF:USA 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Omnicom Health Group acquires Elsevier's Pharma Communications business in Japan, rebrands as EMC K.K.

By PRNewswire PRNewswire • 03-27-2018

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex • 12-14-2012

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe • 08-29-2013

Investing in Information

By Vanina Egea Vanina Egea • 03-06-2014